Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) and Onconova Therapeutics (NASDAQ:ONTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.

Volatility & Risk

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Onconova Therapeutics has a beta of 2.44, meaning that its stock price is 144% more volatile than the S&P 500.

Profitability

This table compares Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and Onconova Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) N/A -23,993.13% -381.50%
Onconova Therapeutics -976.64% -872.01% -145.37%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and Onconova Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) 0 0 1 0 3.00
Onconova Therapeutics 0 0 3 0 3.00

Onconova Therapeutics has a consensus target price of $15.00, indicating a potential upside of 4,900.00%. Given Onconova Therapeutics’ higher possible upside, analysts plainly believe Onconova Therapeutics is more favorable than Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

Earnings & Valuation

This table compares Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and Onconova Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) N/A N/A -$16.65 million ($0.18) -2.17
Onconova Therapeutics $1.23 million 1.46 -$20.57 million ($4.99) -0.06

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) has higher earnings, but lower revenue than Onconova Therapeutics. Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is trading at a lower price-to-earnings ratio than Onconova Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

13.1% of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) shares are held by institutional investors. Comparatively, 39.5% of Onconova Therapeutics shares are held by institutional investors. 51.8% of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) shares are held by insiders. Comparatively, 9.7% of Onconova Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Onconova Therapeutics beats Zomedica Pharmaceuticals Corp (NYSEAMERICAN) on 8 of the 12 factors compared between the two stocks.

About Zomedica Pharmaceuticals Corp (NYSEAMERICAN)

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

About Onconova Therapeutics

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

Receive News & Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and related companies with MarketBeat.com's FREE daily email newsletter.